Summary for Tradename: CELLCEPT
Pharmacology for Tradename: CELLCEPT
Clinical Trials for: CELLCEPT
Study of Gastrointestinal Side Effects in African American Kidney Transplant Recipients Treated With CellCept or Myfortic
Status: Terminated Condition: Kidney Transplantation
Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients
Status: Terminated Condition: Stable Renal Transplant Recipients
A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .
Status: Terminated Condition: Interstitial Cystitis; Painful Bladder Syndrome
Influence of Pantoprazole to the Bioavailability of Myfortic® and CellCept®
Status: Recruiting Condition: Immunosuppressive Medication After Renal Transplantation; Concomitant Medication After Renal Transplantation
A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)
Status: Not yet recruiting Condition: Renal Transplantation
Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis
Status: Completed Condition: Systemic Lupus Erythematosus; Arthritis
Myfortic vs. Cellcept in Kidney Transplant Recipients
Status: Completed Condition: End Stage Renal Disease
Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation
Status: Completed Condition: Renal Transplant
Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
Status: Completed Condition: Autoimmune Disease
PK-PD Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients
Status: Completed Condition: Kidney Transplant
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|CAPSULE;ORAL||050722||May 3, 1995||RX||Yes||<disabled>||<disabled>|
|SUSPENSION;ORAL||050759||Oct 1, 1998||RX||Yes||5,688,529||<disabled>||Y||<disabled>|
|TABLET;ORAL||050723||Jun 19, 1997||RX||Yes||<disabled>||<disabled>|
mycophenolate mofetil hydrochloride
|INJECTABLE;INJECTION||050758||Aug 12, 1998||RX||Yes||5,543,408||<disabled>||Y||<disabled>|
|This preview shows a limited data set|
Complete access is available with a Subscription
Export unavailable in trial.
Subscribe for complete access.
|mycophenolic mofetil||For Oral Suspension||200 mg/mL||Cellcept||3/25/2011|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639